ZYBERNO
Stock Report
Updated Sep 1, 2026

Quince Therapeutics, Inc. (QNCX)

Healthcare • NASDAQ

$32.57

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
10.0/100
POOR BUSINESS
Quince Therapeutics, Inc. (QNCX) scores 10/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-1,190.0%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Quince Therapeutics, Inc. (QNCX) stock report — Zyberno Score 10/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, QNCX generated -$39.53M in Owner Earnings. Capital was deployed as follows: $204.00K invested in capital expenditures. Reinvestment rate: -0.2%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:32.57
Market Cap:$32.16M

Valuation Multiples (1)

Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:-$83.10M

Price Action & Momentum (1)

% of 52-Week High:3.6%
B. Profitability Assessment

Return Metrics (4)

ROA:-104.5%
Reinvestment Rate:-0.2%
Fundamental Growth Rate (g):2.6%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$30.64
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-12,773.2%
Latest Earnings Filed:2026-08-14
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:14.52x
Quick Ratio:14.52x
Cash Ratio:13.64x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:114,911,000.00
Cash And Cash Equivalents:115,981,000.00
Long Term Debt:$716.00K
Net Debt:-$115.27M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$127.16M

Bottom Line Performance (3)

-$92.48M
Income Before Tax:-$14.98M
Ebitda Ttm:-127,044,000.00

Operating Expenses (5)

Operating Expenses:127,155,000.00
R And D Expense:32,990,000.00
Sga Expense:27,809,000.00
Income Tax Expense:-$2.16M
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$124.00M
Current Assets:$123.41M
Ppe Net:506,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:159,319,000.00
Current Liabilities:8,500,000.00
Long Term Debt:$716.00K
Short Term Debt:$0.00

Equity & Capital (3)

Equity:-$35.32M
Retained Earnings:-$500.03M
Common Stock:250,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:4,636,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:12,093,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$39.45M-$39.66M

Investment Activities (2)

Investing Cash Flow:$12.00M
Capital Expenditures Ttm:204,000.00

Financing Activities (3)

Financing Cash Flow:$9.44M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:111,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-9.71
-$10.43
Earnings Per Share Ttm:-$93.65

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$41.95

Book Value & Capital (2)

Book Value Per Share:-$35.77
Cash Per Share:117.45

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:60.00
Quality Score:20.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$39.53M

Damodaran Growth Analysis (2)

Reinvestment Rate:-0.2%
Fundamental Growth Rate (g):2.6%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-50.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:QNCX
Company Name:Quince Therapeutics, Inc.
Sector:Healthcare
Industry:Biological Products, (No Diagnostic Substances)
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:987.49K
Shares Outstanding Basic:6.13M
Shares Outstanding Diluted:6.13M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 12:44:57 UTC
Data Timestamp:2026-08-21T06:13:13.667859
Scroll to Top